CoChat

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Open access

The DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.

Abstract

We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints were progression-free survival (PFS) in intent-to-treat and PD-L1+ populations. Intent-to-treat PFS hazard ratios for atezolizumab + bevacizumab or atezolizumab monotherapy versus sunitinib were 1.0 (95% confidence interval (CI), 0.69-1.45) and 1.19 (95% CI, 0.82-1.71), respectively; PD-L1+ PFS hazard ratios were 0.64 (95% CI, 0.38-1.08) and 1.03 (95% CI, 0.63-1.67), respectively. Exploratory biomarker analyses indicated that tumor mutation and neoantigen burden were not associated with PFS. Angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments. These molecular profiles suggest that prediction of outcomes with anti-VEGF and immunotherapy may be possible and offer mechanistic insights into how blocking VEGF may overcome resistance to immune checkpoint blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0053-3

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 1,260

Metadata

Authors
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R., Gruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D., & Powles, T.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Genentech (US)
  • Georgetown Lombardi Comprehensive Cancer Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Cleveland Clinic (US)
  • Institut Gustave Roussy (FR)
  • University of California, San Francisco (US)
  • Mayo Clinic in Florida (US)
  • City Of Hope National Medical Center (US)
  • Florida Cancer Specialists & Research Institute (US)
  • Yale University (US)
  • Sarah Cannon (US)
  • Vanderbilt University Medical Center (US)
  • University of Chicago (US)
  • Royal Marsden Hospital (GB)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Universitat Autònoma de Barcelona (ES)
  • Azienda Ospedaliera Universitaria Senese (IT)
  • Medizinische Hochschule Hannover (DE)
  • Dana-Farber Cancer Institute (US)
  • Roche (United Kingdom) (GB)
  • Queen Mary University of London (GB)
Corresponding author
McDermott, David F.
Venue
Nature Medicine
Published
2018-06
Volume
24
Issue
6
Pages
749-757
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2805302875
Cited by
1,260
References
69
Citations by year
2026: 83 · 2025: 100 · 2024: 127 · 2023: 168 · 2022: 227 · 2021: 195 · 2020: 203 · 2019: 117 · 2018: 37
FWCI
103.97
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (P50CA101942, P30CA008748, P30CA014599, P30CA068485)
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
atezolizumab, bevacizumab, sunitinib, metastatic renal cell carcinoma, PD-L1 blockade, anti-VEGF therapy, combination immunotherapy, progression-free survival, PD-L1 expression, tumor mutational burden, neoantigens, angiogenesis, IFN-gamma response, immune checkpoint inhibitor resistance, predictive biomarkers
MeSH terms
Bevacizumab, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Mutation, Gene Expression Regulation, Neoplastic, Treatment Outcome, Gene Expression Profiling, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. https://app.cochat.ai/papers/10.1038/s41591-018-0053-3
The paper
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., . . . Powles, T. (2018). Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-018-0053-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.